Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 20/20 | 0.72 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.61 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.56 |
| ▸ | POU2F2 | P09086 | 1/20 | 0.56 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.56 |
| ▸ | POU2F1 | P14859 | 1/20 | 0.56 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.56 |
| ▸ | HRH2 | P25021 | 1/20 | 0.56 |
| ▸ | MC4R | P32245 | 1/20 | 0.56 |
| ▸ | FAP | Q12884 | 1/20 | 0.56 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.56 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.56 |
| ▸ | GHSR | Q92847 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29120526 | 0.85 | ALDH1A1 (0.53) | DPP4CHRM1GPR119 | |
| SCHEMBL29120524 | 0.85 | ALDH1A1 (0.53) | DPP4CHRM1GPR119 | |
| SCHEMBL27944320 | 0.84 | DPP4 (0.69) | DPP4CHRM1POU2F2ADORA3POU2F1 | |
| SCHEMBL555442 | 0.84 | DPP4 (1.00) | DPP4CHRM1GPR119POU2F2ADORA3 | |
| SCHEMBL26661361 | 0.83 | DPP4 (0.55) | DPP4CHRM1 | |
| SCHEMBL26661367 | 0.83 | DPP4 (0.55) | DPP4CHRM1 | |
| SCHEMBL4668663 | 0.82 | TSHR (0.73) | DPP4 | |
| SCHEMBL3693491 | 0.82 | DPP4 (0.61) | DPP4CHRM1 | |
| SCHEMBL556008 | 0.82 | DPP4 (0.73) | DPP4CHRM1CHRM3 | |
| SCHEMBL17124944 | 0.81 | TSHR (0.54) | DPP4CHRM1POU2F2ADORA3POU2F1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3453403-B1 | DPP-IV INHIBITOR COMBINED WITH A FURTHER ANTIDIABETIC AGENT, TABLETS COMPRISING SUCH FORMULATIONS, THEIR USE AND PROCESS FOR THEIR PREPARATION | BOEHRINGER INGELHEIM INT (DE) | 2025-01-22 | — | — | EP | claimed |
| EP-2397142-B1 | Use of DPP IV inhibitors | BOEHRINGER INGELHEIM INT (DE) | 2022-07-27 | — | — | EP | claimed |
| CN-109761983-B | Preparation method of linagliptin | 深圳市第二人民医院 | 2022-03-04 | — | — | CN | claimed |
| US-11919903-B2 | Polymorphs | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2024-03-05 | — | — | US | disclosed |
| US-11911387-B2 | Vasoprotective and cardioprotective antidiabetic therapy | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2024-02-27 | — | — | US | disclosed |
| EP-4104838-A1 | Use of DPP IV inhibitors | Boehringer Ingelheim International GmbH (DE) | 2022-12-21 | — | — | EP | disclosed |
| EP-2397142-B1 | Use of DPP IV inhibitors | BOEHRINGER INGELHEIM INT (DE) | 2022-07-27 | — | — | EP | disclosed |
| CN-109761983-B | Preparation method of linagliptin | 深圳市第二人民医院 | 2022-03-04 | — | — | CN | disclosed |
| CN-109761983-B | Preparation method of linagliptin | 深圳市第二人民医院 | 2022-03-04 | — | — | CN | disclosed |
| CN-103319483-A | Preparation method of important intermediate of linagliptin | 2Y CHEM LTD | 2013-09-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11911387-B2 | Vasoprotective and cardioprotective antidiabetic therapy | DPP4, DPP3, DPP7 | DPP4 1/4885CHRM1 3148/4885GPR119 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.